cyyr1 Antibody

What is CYYR1 protein and where is it primarily expressed?

CYYR1 is a membrane-localized protein encoded by a gene located on human chromosome 21. Initially characterized as a protein of unknown function, recent research has revealed its role in regulating ubiquitination and degradation of other proteins, particularly the E3 ubiquitin ligase WWP1. CYYR1 contains three PPxY motifs that are crucial for protein-protein interactions with WW domain-containing proteins . Expression analyses have shown that CYYR1 is predominantly found in cells belonging to the diffuse neuroendocrine system (DNES), which can be the origin of neuroendocrine tumors . Interestingly, CYYR1 expression is significantly decreased in breast cancer and is associated with favorable clinical outcomes . At the subcellular level, CYYR1 localizes to late endosomal vesicles and directs polyubiquitinated WWP1 toward lysosomal degradation through binding to ANKRD13A .

What applications are CYYR1 antibodies validated for in research?

CYYR1 antibodies have been validated for several research applications:

• Immunohistochemistry (IHC): Commercial antibodies like E-AB-18980 are validated for IHC applications with recommended dilutions of 1:50-1:300, particularly for detecting CYYR1 in human esophageal cancer samples .

• Western Blotting: CYYR1 antibodies have been used to detect endogenous CYYR1 in cell lysates, with validation through siRNA-mediated depletion to confirm specificity .

• Immunoprecipitation: Antibodies have successfully immunoprecipitated endogenous CYYR1 and co-immunoprecipitated interaction partners like WWP1 and WWP2 .

• Proximity Ligation Assay (PLA): CYYR1 antibodies have been employed in PLA to visualize and confirm proximity between endogenous CYYR1 and its binding partners such as WWP1 in situ .

The reactivity of commercially available antibodies like E-AB-18980 includes human and mouse CYYR1 proteins, with verified samples including human esophagus cancer tissue .

How can researchers validate the specificity of CYYR1 antibodies?

Validating CYYR1 antibody specificity requires a multi-method approach:

• siRNA-mediated knockdown: Deplete CYYR1 using two independent siRNAs and confirm reduced signal by Western blot. This approach has been successfully used in previous studies with MDA-MB-468 cells that express endogenous CYYR1 .

• Overexpression controls: Compare antibody signal in cells with and without CYYR1 overexpression.

• Tissue specificity validation: Test the antibody on tissues known to express CYYR1 (neuroendocrine tissues) versus non-expressing tissues as negative controls.

• Cross-reactivity assessment: Ensure the antibody doesn't detect related proteins by testing in knockout models or with recombinant proteins.

• Multiple antibody comparison: Validate observations using different antibodies targeting distinct epitopes of CYYR1.

Researchers should note that very few breast cancer cell lines express CYYR1 mRNA, with MDA-MB-468 being one confirmed line where endogenous CYYR1 can be detected .

What are the optimal protocols for immunohistochemistry with CYYR1 antibodies?

For optimal immunohistochemical detection of CYYR1, follow this protocol based on validated antibodies like E-AB-18980:

Sample preparation:

• Fix tissues in 10% buffered formalin for 24-48 hours

• Process and embed in paraffin

• Cut sections at 4-5 μm thickness

Staining protocol:

• Deparaffinize and rehydrate sections through xylene and graded alcohols

• Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) for 15-20 minutes

• Block endogenous peroxidase activity with 3% H₂O₂ in methanol for 10 minutes

• Block non-specific binding with 5% normal serum for 1 hour

• Incubate with primary anti-CYYR1 antibody at 1:50-1:300 dilution (optimize for each lot) overnight at 4°C

• Apply appropriate secondary detection system (HRP-polymer recommended)

• Develop with DAB and counterstain with hematoxylin

• Dehydrate, clear, and mount

Critical considerations:

• Always include positive controls (human esophagus cancer has been verified)

• Include negative controls (primary antibody omission and isotype controls)

• Optimize antibody dilution for each new lot to maintain consistent staining

• For dual staining with WWP1, consider sequential staining protocols with thorough blocking between antibody applications

What troubleshooting approaches are effective when CYYR1 antibodies yield high background?

High background is a common challenge when working with CYYR1 antibodies. Here are methodological solutions:

• Antibody dilution optimization:

  • Test a wider dilution range (1:50 to 1:500)

  • Perform titration experiments to find the optimal signal-to-noise ratio

• Blocking enhancement:

  • Increase blocking time to 2 hours

  • Try alternative blocking solutions (5% BSA, 10% normal serum, or commercial blocking reagents)

  • Add 0.1-0.3% Triton X-100 to blocking solution for better penetration

• Washing optimization:

  • Increase wash duration (5 × 5 minutes)

  • Use PBS-T (PBS with 0.1% Tween-20) instead of PBS alone

  • Ensure temperature consistency during washes (room temperature)

• Antibody diluent modification:

  • Add 0.05% Tween-20 to antibody diluent

  • Include 1% BSA in the antibody diluent

  • Consider commercial antibody diluents with background-reducing components

• Signal amplification system adjustment:

  • Switch between polymer-based and biotin-streptavidin systems

  • Reduce incubation time of the detection system

• Tissue-specific treatments:

  • Pre-treat sections with 0.1% Sudan Black B in 70% ethanol to reduce lipofuscin autofluorescence

  • Use copper sulfate treatment to quench endogenous fluorescence

For Western blotting, increasing blocking concentration (5% milk or BSA) and adding 0.1% Tween-20 to wash buffers can significantly reduce background.

How do polyclonal and monoclonal CYYR1 antibodies compare in research applications?

Table 1: Comparative Analysis of Polyclonal vs. Monoclonal CYYR1 Antibodies

Key methodological considerations:

• For initial detection and localization studies, polyclonal antibodies like E-AB-18980 offer broader epitope recognition

• For distinguishing between the CAG+ and CAG- splice isoforms of CYYR1, custom monoclonal antibodies targeting the splice junction would be ideal

• For reproducible quantitative assays, monoclonal antibodies provide more consistent results across experiments

• When studying CYYR1-WWP1 interactions, consider that polyclonal antibodies might recognize epitopes involved in protein-protein interactions, potentially interfering with complex formation

How can researchers investigate CYYR1-WWP1 interactions in breast cancer cell lines?

Investigating CYYR1-WWP1 interactions in breast cancer requires a comprehensive experimental approach:

• Cell line selection and preparation:

  • Use MDA-MB-468 cells that naturally express CYYR1

  • For cell lines lacking CYYR1 expression, establish tetracycline-inducible expression systems as demonstrated with MDA-MB-231 cells

  • Consider paired isogenic models with and without CYYR1 expression

• Protein-protein interaction analysis:

  • Co-immunoprecipitation (Co-IP): Immunoprecipitate endogenous CYYR1 using validated antibodies and detect co-precipitated WWP1 by Western blotting

  • Proximity Ligation Assay (PLA): Visualize endogenous CYYR1-WWP1 interactions in situ using specific antibodies against each protein

  • Domain mapping: Use recombinant constructs expressing specific domains (WW domains of WWP1, PPxY motifs of CYYR1) to determine critical interaction regions

• Functional analysis of the interaction:

  • Ubiquitination assays: Co-express Flag-WWP1, HA-CYYR1 (wild-type or mutants), and His-Ubiquitin in HEK293 cells, then isolate ubiquitinated proteins by Ni-NTA pull-down and analyze WWP1 ubiquitination by anti-Flag Western blot

  • Protein stability assessment: Perform cycloheximide chase experiments to monitor WWP1 degradation kinetics with and without CYYR1 expression

  • Lysosomal inhibition: Treat cells with bafilomycin A1 or chloroquine to confirm the lysosomal degradation pathway of WWP1 induced by CYYR1

• Cellular consequence evaluation:

  • Colony formation assays: Assess how CYYR1 expression affects anchorage-dependent and -independent growth

  • Proliferation and migration assays: Determine if CYYR1-mediated WWP1 degradation affects cancer cell proliferation and motility

  • Gene expression analysis: Identify downstream targets affected by the CYYR1-WWP1 axis

Research has demonstrated that CYYR1 expression leads to K63-linked polyubiquitination of WWP1, directing it to lysosomal degradation rather than proteasomal degradation, and this mechanism depends on the PPxY motifs in CYYR1 .

What methodologies are optimal for analyzing alternative splicing isoforms of CYYR1?

CYYR1 undergoes subtle alternative splicing that generates two isoforms: CAG+ (including an alanine residue at the exon 3/exon 4 junction) and CAG- (lacking this residue) . Here are methodological approaches for their analysis:

• RT-PCR-based detection and quantification:

  • Primer design strategy:

    • Forward primer common to both isoforms (e.g., 5'-GTCTTGCTTCCGAAGTTGGTCCTGC-3' based on exon 1)

    • Isoform-specific reverse primers spanning the exon 3/exon 4 junction:

      • CAG- primer: 5'-GTGACCGTAGGGTGGTGGTCCAGG-3'

      • CAG+ primer: 5'-GTGACCGTAGGGTGGTGGTCCTGC-3'

    • These primers include two mismatches at the last three bases to ensure specificity

  • PCR protocol:

    • Initial denaturation: 94°C for 2 minutes

    • 35-40 cycles: 94°C for 30 seconds, 63°C for 30 seconds, 72°C for 45 seconds

    • Final extension: 72°C for 7 minutes

  • Analysis:

    • Separate products on 2% agarose gels (expected size: 321 bp for CAG-, 324 bp for CAG+)

    • Quantify band intensity using densitometry

    • Normalize to housekeeping genes like β2-microglobulin

• Real-time quantitative PCR:

  • Design TaqMan probes specific to each isoform

  • Perform absolute quantification using standard curves

  • Calculate the CAG+/CAG- ratio across different samples

• RNA-Seq analysis:

  • Perform deep sequencing with sufficient coverage at the exon 3/exon 4 junction

  • Use computational tools for alternative splicing detection

  • Validate findings by RT-PCR

• Tissue distribution analysis:

  • Compare CAG+/CAG- ratios between normal and tumor tissues

  • Analyze correlation between isoform ratio and clinical parameters

This subtle alternative splicing of CYYR1 may have functional implications, as demonstrated in studies of neuroendocrine tumors where both isoforms were detected with varying ratios .

How does CYYR1 regulate the ubiquitination pathway and what are the implications for cancer research?

CYYR1 has emerged as an important regulator of the ubiquitination pathway, particularly affecting E3 ubiquitin ligases of the NEDD4 family. Here's a methodological analysis of this regulation and its implications:

• Molecular mechanism of CYYR1-mediated regulation:

  • CYYR1 binds to WW domains of WWP1, WWP2, and ITCH through its PPxY motifs

  • This interaction triggers K63-linked autoubiquitination of WWP1, rather than K48-linked ubiquitination

  • CYYR1 directs ubiquitinated WWP1 toward lysosomal degradation by:

    • Localizing to Rab7-positive late endosomes

    • Recruiting ANKRD13A as an adaptor for the endosomal-lysosomal pathway

• Experimental approaches to study this mechanism:

  • Ubiquitination analysis:

    • Co-express HA-CYYR1 (wild-type or mutants), Flag-WWP1 (wild-type or catalytically inactive), and His-Ubiquitin

    • Isolate ubiquitinated proteins by Ni-NTA pulldown

    • Analyze ubiquitination patterns using ubiquitin linkage-specific antibodies (K48-Ub vs. K63-Ub)

  • Degradation pathway identification:

    • Proteasome inhibition with MG132 (no effect on CYYR1-mediated WWP1 degradation)

    • Lysosome inhibition with bafilomycin A1 and chloroquine (prevents CYYR1-mediated WWP1 degradation)

• Cancer implications:

  • Expression patterns:

    • CYYR1 expression is decreased in breast cancer tissues

    • WWP1 is frequently amplified in breast cancer and associated with poor prognosis

    • CYYR1 overexpression attenuates breast cancer cell growth in colony formation assays

  • Functional significance:

    • CYYR1 may function as a tumor suppressor by targeting oncogenic WWP1 for degradation

    • This mechanism depends on CYYR1's PPxY motifs, as their deletion abolishes both WWP1 binding and growth suppression

Table 2: Effects of CYYR1 Variants on WWP1 Regulation

These findings establish CYYR1 as a novel regulator of ubiquitin ligase stability, with potential implications for therapeutic approaches targeting the CYYR1-WWP1 axis in breast cancer .

Can CYYR1 serve as a prognostic marker in cancer research?

CYYR1 shows promise as a prognostic biomarker in cancer research, particularly in breast cancer. Here's a methodological framework for evaluating its prognostic value:

Research has demonstrated that CYYR1 expression is significantly decreased in breast cancer and associated with beneficial clinical outcomes . This aligns with its functional role in promoting the degradation of WWP1, an oncogenic E3 ubiquitin ligase frequently amplified in breast cancer and associated with poor prognosis .

Future studies should explore CYYR1's prognostic value in neuroendocrine tumors, where its expression is naturally high in the cells of origin (DNES) , and determine whether specific isoforms have differential prognostic significance.

What approaches should researchers use to study the subcellular localization of CYYR1?

Studying CYYR1's subcellular localization requires a multi-technique approach:

• Immunofluorescence microscopy:

  • Basic protocol:

    • Fix cells with 4% paraformaldehyde (10 minutes)

    • Permeabilize with 0.1% Triton X-100 (5 minutes)

    • Block with 5% BSA (1 hour)

    • Incubate with CYYR1 antibody at validated dilution (overnight, 4°C)

    • Apply fluorophore-conjugated secondary antibodies

    • Counterstain nuclei with DAPI

  • Co-localization studies:

    • Label with markers of subcellular compartments:

      • Late endosomes: Rab7, LAMP1

      • Plasma membrane: Na⁺/K⁺ ATPase

      • Early endosomes: EEA1

      • Golgi apparatus: GM130

    • Perform quantitative co-localization analysis (Pearson's correlation coefficient)

• Biochemical fractionation:

  • Separate cellular components by differential centrifugation

  • Isolate membrane fractions, cytosol, and organelles

  • Analyze CYYR1 distribution by Western blotting

  • Include compartment-specific markers as controls

• Live-cell imaging:

  • Generate fluorescent protein fusions (CYYR1-GFP or CYYR1-mCherry)

  • Validate that the fusion protein maintains native localization and function

  • Track dynamic movements between cellular compartments

  • Perform photobleaching experiments to assess protein mobility

• Electron microscopy:

  • Immunogold labeling for precise localization at ultrastructural level

  • Evaluate association with membrane structures and vesicles

Research has shown that CYYR1 localizes to late endosomal vesicles and directs polyubiquitinated WWP1 toward lysosomal degradation through binding to ANKRD13A . This localization is functionally important for CYYR1's role in regulating WWP1 stability and subsequent effects on cell growth.

How should researchers design experiments to elucidate CYYR1 function in neuroendocrine tumors?

Elucidating CYYR1 function in neuroendocrine tumors (NETs) requires a comprehensive experimental strategy:

• Expression profiling in NET samples:

  • IHC analysis: Screen a cohort of different NET types for CYYR1 expression

  • RT-PCR quantification: Measure total CYYR1 mRNA and CAG+/CAG- isoform ratio

  • Correlation analysis: Associate CYYR1 expression with NET subtypes, grade, and patient outcomes

• Cellular models:

  • Cell line selection: Identify NET cell lines expressing CYYR1 or establish expression models

  • Gene manipulation strategies:

    • CRISPR-Cas9 knockout of CYYR1

    • Stable overexpression of wild-type CYYR1 and functional mutants (ΔPPxY)

    • Inducible expression systems for temporal control

    • Isoform-specific expression (CAG+ vs. CAG-)

• Functional assays:

  • Proliferation: MTT/WST-1 assays, BrdU incorporation, colony formation

  • Differentiation: Analysis of neuroendocrine markers (chromogranin A, synaptophysin)

  • Secretory function: Measurement of hormone/neuropeptide release

  • Migration/invasion: Wound healing and transwell assays

• Molecular interaction studies:

  • Interactome analysis: Immunoprecipitation followed by mass spectrometry

  • WWP1/WWP2 pathway analysis: Assess whether the CYYR1-WWP1 regulatory axis observed in breast cancer is conserved in NETs

  • Signaling pathway impact: Examine effects on PI3K/AKT, mTOR, and Notch pathways

• Animal models:

  • Xenograft studies: Implant NET cells with modulated CYYR1 expression

  • Patient-derived xenografts: Assess correlation between CYYR1 levels and tumor growth

  • Genetic models: Consider transgenic models with tissue-specific CYYR1 alterations

Experimental protocol for evaluating CYYR1 isoforms in NETs:

• Extract RNA from NET specimens

• Perform RT-PCR with isoform-specific primers as described previously

• Calculate the CAG+/CAG- ratio across different NET subtypes

• Correlate this ratio with tumor characteristics and patient outcomes

• Functionally express each isoform separately in NET cell models to identify isoform-specific effects

This approach would help determine whether CYYR1 functions as a tumor suppressor in NETs similar to its role in breast cancer , and whether its high expression in cells of the diffuse neuroendocrine system (DNES) has functional significance for NET biology and treatment.